Why Veru Stock Is Crashing Today?
The FDA declined to grant Veru Inc’s (NASDAQ:VERU) request for Emergency Use Authorization (EUA) for sabizabulin to treat hospitalized adult patients…
Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study
Praxis Precision Medicines Inc (NASDAQ:PRAX) announced topline results from the Essential1 study evaluating the efficacy, safety, and tolerability of ulixacaltamide (PRAX-944)…
Alpha Tau Announces Grant Of Expanded Radioactive License And Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters
Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli
Praxis Precision Medicines’s Essential1 Study Evaluating Ulixacaltamide (PRAX-944) For Essential Tremor Did Not Reach Statistical Significance On Primary Endpoint, Change From Baseline To Day 56 In The Modified Activities Of Daily Living (mADL) Score
Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary efficacy endpoint relative to placebo that did not reach statistical significance (p=0.126), and achieved nominal
Incannex Has Engaged Catalent To Develop And Manufacture A cGMP-grade Psilocybin Drug Product For Use In Incannex’s Proprietary Psilocybin-assisted Psychotherapy Drug Development Program And, Potential Wider Commercial Use
Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation
The European Commission Has Approved Bristol Myers Squibb’s Reblozyl (Luspatercept) For Anemia Associated With Non-transfusion-dependent Beta-thalassemia
The EC approval of Reblozyl was based on results from the Phase 2 BEYOND study, evaluating the efficacy and safety of Reblozyl versus placebo in 145 adults with NTD beta thalassemia. Patients were
Verve Therapeutics Reported New Preclinical Data In Non-human Primates Demonstrating Potent, Durable, And Well-tolerated Editing Of The ANGPTL3 Gene Following The Administration Of VERVE-201
VERVE-201 aims to reduce the heavy treatment burden associated with available therapies for HoFH including the requirement for multiple oral, injectable, and intravenous infusions in each patient, often administered over
Exelixis’ Phase 3 CONTACT-03 Study Did Not Meet Its Primary Endpoint Of Progression-Free Survival; Shares Fall
CONTACT-03 evaluated cabozantinib plus atezolizumab versus cabozantinib for locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal cell carcinoma (RCC) who progressed during
Reported Late Thursday, March 2, Terns Pharmaceuticals’ Program Updates; Q3 Adjusted Cash Balance As Of Sept 30, 2022, Of $293M Provides Cash Runway Into 2026
Completes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in the third quarter of 2023
On track to initiate U.S. clinical trial
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
As previously announced, Valneva SE (NASDAQ:VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new…